

## Literatur

- Schmoldt A, Benthe HF, Haberland G. Digitoxin metabolism by rat liver microsomes. *Biochemical pharmacology*. 1975;24:1639-1641. doi:10.1258%2Fjbrsm.2012.12k044.
- Dai L, Gao GF. Viral targets for vaccines against COVID-19. *Nat Rev Immunol*. 2021;21:73–82. doi:10.1038/s41577-020-00480-0.
- van Lint S, Heirman C, Thielemans K, Breckpot K. mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. *Hum Vaccin Immunother*. 2013;9:265–74. doi:10.4161/hv.22661.
- Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – a new era in vaccinology. *Nat Rev Drug Discov*. 2018;17:261–79. doi:10.1038/nrd.2017.243.
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;383:2603–15. doi:10.1056/NEJMoa2034577.
- Zhang N-N, Li X-F, Deng Y-Q, Zhao H, Huang Y-J, Yang G, et al. A Thermostable mRNA Vaccine against COVID-19. *Cell*. 2020;182:1271–1283.e16. doi:10.1016/j.cell.2020.07.024.
- BioNTech Manufacturing GmbH. mRNA-Impfstoffe zur Bekämpfung der COVID-19 Pandemie. <https://biontech.de/de/covid-19-portal/mrna-impfstoffe>. Accessed 16 Mar 2022.
- Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, et al. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. *Immunity*. 2020;53:724–732.e7. doi:10.1016/j.immuni.2020.07.019.
- Lederer K, Castaño D, Gómez Atria D, Oguin TH, Wang S, Manzoni TB, et al. SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. *Immunity*. 2020;53:1281–1295.e5. doi:10.1016/j.immuni.2020.11.009.
- Locht C. Vaccines against COVID-19. *Anaesth Crit Care Pain Med*. 2020;39:703–5. doi:10.1016/j.jaccpm.2020.10.006.
- Roßmann L, Bagola K, Stephen T, Gerards A-L, Walber B, Ullrich A, et al. Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response. *Proc Natl Acad Sci U S A* 2021. doi:10.1073/pnas.2103651118.
- Steinle H, Behring A, Schlensak C, Wendel HP, Avci-Adali M. Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges. *Stem Cells*. 2017;35:68–79. doi:10.1002/stem.2402.
- Hogan MJ, Pardi N. mRNA Vaccines in the COVID-19 Pandemic and Beyond. *Annu Rev Med*. 2022;73:17–39. doi:10.1146/annurev-med-042420-112725.
- Open Access Government. BioNTech will ship mobile mRNA vaccine factories to Africa. <https://www.openaccessgovernment.org/mrna-vaccine-factories/129927/>. Accessed 18 Mar 2022.
- Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. *Science*. 1990;247:1465–8. doi:10.1126/science.1690918.
- Newey S. Moderna reveals vaccine plans for 15 'priority pathogens': The company is already working to protect against some of the diseases, which include dengue, Ebola, malaria, Marburg and Lassa fever. 08.03.2022. <https://www.telegraph.co.uk/global-health/science-and-disease/moderna-reveals-vaccine-plans-15-priority-pathogens/>. Accessed 16 Mar 2022.
- Ballesteros-Briones MC, Silva-Pilipich N, Herrador-Cañete G, Vanrell L, Smerdou C. A new generation of vaccines based on alphavirus self-amplifying RNA. *Curr Opin Virol*. 2020;44:145–53. doi:10.1016/j.coviro.2020.08.003.
- Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: Challenges and bottlenecks. *Vaccine*. 2021;39:2190–200. doi:10.1016/j.vaccine.2021.03.038.